Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Scientists conducted an investigator-initiated, multicenter, single-group, Phase II study of the anti–programmed death ligand 1 agent atezolizumab in adult and pediatric patients with advanced alveolar soft part sarcoma.